The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.

The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.

The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.

The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.

Provided herein are compositions and methods for reducing toxicity associated with TAR DNA-binding protein 43. Certain embodiments of the present disclosure are related to compositions that treat, inhibit, reduce, prevent, or delay a disease or condition associated with TDP-43 toxicity, such as cystic fibrosis or neurodegenerative diseases. Certain embodiments of the present disclosure are related to methods of treating, inhibiting, reducing, preventing, or delaying a disease or condition associated with TDP-43 toxicity by administering compounds of any one of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) to a subject in need.

This invention relates to heterocyclic compounds and their use in medicine. In particular, the present invention discloses heterocyclic compound of formula I, or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The invention also relates to the use of these compounds in medicine.

The present invention relates to a novel quinolinone derivative compound that regulates intracellular signal transduction mediated by TSLP and IL-33 to exhibit efficacy in preventing or treating allergic diseases such as asthma or atopic dermatitis. The quinolinone derivative compound of the present invention can effectively suppress inflammatory responses of allergic diseases such as asthma or atopic dermatitis. The present invention also relates to a pharmaceutical composition including the quinolinone derivative compound. The pharmaceutical composition of the present invention can be used to fundamentally prevent or treat various allergic and asthmatic diseases.

Methods for treating and differential diagnosis between ACTH-Dependent and ACTH-Independent Cushing's syndrome are disclosed, in which a glucocorticoid receptor antagonist (GRA) is administered to a Cushing's syndrome patient with a basal ACTH level less than about 25 pg/mL. If i) the patients blood ACTH and ii) the patients blood cortisol, or adrenal hormone, or adrenal pre-hormone levels rise, or if the ACTH:cortisol ratio increases, then ACTH-Dependent Cushing's syndrome is diagnosed. If those levels do not rise, or if the ACTH:cortisol ratio decreases, then ACTH-Independent Cushing's syndrome is diagnosed. In some instances, the patient is recovering from surgery to remove an ACTH secreting tumor, and the method described herein is used to determine if the tumor resection was successful or complete. The GRA may be mifepristone, or a non-steroidal GRA having a heteroaryl-ketone fused azadecalin backbone, an octahydro fused azadecalin backbone, a cyclohexyl pyrimidine backbone, or a fused azadecalin backbone.

A bag system for containing a nutritional composition includes a pouch for holding a nutritional composition front and rear panels which are welded to each other by a bottom weld and a top weld and two welds on each opposed side; and a port for filling and. dispensing for feeding at the top of the pouch with a cap/lid to be resealable. An 8 French tube or larger is connected at the port for delivering the composition without dilution and via enteral pump delivery, A nutritional composition has fatty acids; dietary fibers; carbohydrates; a vitamin and mineral blend; proteins; and a whole food blend. A nutritionally complete nutrient composition for enteral feeding comprises a whole food blend and additional nutrients. Preferably; the nutrient composition is provided in a squeezable serving pouch. The nutrient composition is free of major allergens.

A bag system for containing a nutritional composition includes a pouch for holding a nutritional composition front and rear panels which are welded to each other by a bottom weld and a top weld and two welds on each opposed side; and a port for filling and. dispensing for feeding at the top of the pouch with a cap/lid to be resealable. An 8 French tube or larger is connected at the port for delivering the composition without dilution and via enteral pump delivery, A nutritional composition has fatty acids; dietary fibers; carbohydrates; a vitamin and mineral blend; proteins; and a whole food blend. A nutritionally complete nutrient composition for enteral feeding comprises a whole food blend and additional nutrients. Preferably; the nutrient composition is provided in a squeezable serving pouch. The nutrient composition is free of major allergens.